Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sandostatin LAR in advanced hepatocellular carcinoma
ACTRN12605000699662Phase 2Active, not recruiting
- Sponsor
- Site - Investigator Initiated
- Start
- Apr 2001
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of octreotide in hepatocellular carcinoma (HCC), sponsored by Site - Investigator Initiated. Primary endpoints: Compliance with treatment and Compliance with assessments. Started Apr 2001; status: active, not recruiting.
02
Drugs
octreotide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ACTRN12605000699662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000699662.